December 6, 2010
Genentech, a member of the Roche Group, achieved positive results from a Phase II study of RG16781, an investigational glycine reuptake inhibitor (GRI) for the treatment of schizophrenia.
November 29, 2010
Pfizer and Protalix BioTherapeutics have submitted a Marketing Authorization Application to the EMA for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD), for the treatment of Gaucher disease.
November 24, 2010
Eli Lilly and Co. and Acrux received approval from the FDA for Axiron (testosterone) topical solution CIII for replacement therapy in men for conditions associated with a deficiency or absence of testosterone.
November 23, 2010
Abbott achieved positive results from a Phase II dose-ranging study of atrasentan, a highly selective endothelin A receptor antagonist in development to help slow chronic kidney disease (CKD) progression in patients with type 2 diabetic kidney disease.
November 22, 2010
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare achieved positive results from two parallel Phase III studies in patients with the neovascular form of age-related macular degeneration (wet AMD), with all regimens of VEGF Trap-Eye (aflibercept ophthal
November 19, 2010
Pfizer’s Phase III trial studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC) met its primary endpoint, demonstrating significantly extended progression-free survival (PFS) when co
November 5, 2010
Genentech achieved positive results from a Phase II study of RG7204, an investigational molecule designed to selectively inhibit a cancer-causing, mutated form of the BRAF protein found in approximately half of metastatic melanoma tumors.
Sign up now to receive the free weekly newsletter, and more!